Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Titel:
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Auteur:
Kim, Ji-Yeon Im, Seock-Ah Jung, Kyung Hae Ro, Jungsil Sohn, Joohyuk Kim, Jee Hyun Park, Yeon Hee Kim, Tae-Yong Kim, Sung-Bae Lee, Keun Seok Kim, Gun Min Kim, Se Hyun Kim, Seonwoo Ahn, Jin Seok Lee, Kyung-Hun Ahn, Jin-Hee Park, In Hae Im, Young-Hyuck